Prevention is the most promising way to reduce the high personal, familial, societal, clinical and economic costs of mental disorders in Europe and worldwide. A complementary approach is to go beyond the prevention of mental ill health, to promote good mental health. This manuscript highlights the first European consortium fostering cutting-edge multidisciplinary research in these two areas. The ECNP-funded Network on the Prevention of Mental Disorders and Mental Health Promotion (ECNP PMD-MHP) brings together European sites of excellence with different expertise for translational research collaboration, including partnerships with the industry. The ECNP PMD-MHP Network adopts a transdiagnostic, lifespan, clinical staging model which cuts across different mental disorders and different methodologies. The main aims of the ECNP PMD-MHP Network are to facilitate multidisciplinary collaboration, enhance knowledge and data sharing, standardise core assessment and outcome measures, promote clinical research, apply for grant funding, and generate research reports. By supporting collaborative research, the Please cite this article as: P. Fusar-Poli, M. Bauer and S. Borgwardt et al., European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP), European Neuropsychopharmacology, https://doi.org/10.
Introduction
A major barrier to improving outcomes of mental disorders is that after the onset of the disorder has occurred, there are limited treatment possibilities and even fewer options to alter the illness course ( Millan et al., 2016 ) . Thus, prevention is the most promising way to reduce the high personal, familial, societal, clinical and economic costs of mental disorders in Europe and worldwide ( Fusar-Poli et al., 2017a ) . The most validated preventive paradigm has focused on indicated primary prevention ( Table 1 ) ( Arango et al., 2018 ) in individuals presenting with subtle signs and symptoms, such as those at clinical high-risk for psychosis ( Fusar-Poli, 2017 Fusar-Poli et al., 2013a ) or those at risk for bipolar disorders ( Bechdolf et al., 2014 ; Correll et al., 2014 ; Fusar-Poli et al., 2018 ; Leopold et al., 2012 ; Pfennig et al., 2014a Pfennig et al., , 2014b Scott et al., 2017 ) , depression ( Loechner et al., 2018 ; Morrell et al., 2016 ; Rachid, 2018 ) , or anxiety disorders ( Moreno-Peral et al., 2017 ) . Complementary emerging approaches include selective primary prevention , targeting asymptomatic individuals with specific risk factors for mental disorders, and universal primary prevention , which can be applied at scale in the general population ( Berk et al., 2017 ; Radua et al., 2018 ) . Primary prevention interventions seek to lower the incidence of mental disorders and are embedded in a clinical staging ( Berk et al., 2017 ; Radua et al., 2018 ) and transdiagnostic ( Fusar-Poli et al., 2017b ) model and are applied across the life span, encompassing the prenatal period, post-natal development, childhood, adolescence, early and late adulthood ( Berk et al., 2017 ; Morrell et al., 2016 ; Radua et al., 2018 ) . Secondary prevention seeks to lower the prevalence of mental disorders while tertiary prevention seeks to reduce relapses, disability and chronicity: these strategies can fur- Table 1 Classification of preventive approaches in psychiatry integrates the classic public health classification with Gordon's classification of physical illness ( WHO, 2004 ) . Gordon's universal, selective and indicated preventive interventions are included within primary prevention in the public health classification [( WHO, 2004 ) , page 17].
Classic public health classification of prevention
Gordon's classification of prevention of physical illness ( Gordon, 1983 ) Primary prevention seeks to prevent the onset (incidence) of a disorder or illness [( WHO, 2004 ) , page 17, Box 2] Universal prevention is defined as those interventions that are targeted at the general public or to a whole population group that has not been identified on the basis of increased risk : targeted at the general public [( WHO, 2004 ) , page 17, Box 3]. Selective prevention targets individuals or subgroups of the population whose risk of developing a mental disorder is significantly higher than average, as evidenced by biological, psychological or social risk factors [( WHO, 2004 ) , page 17, Box 3]. Indicated prevention targets high-risk people who are identified as having minimal but detectable signs or symptoms foreshadowing mental disorder or biological markers indicating predisposition for mental disorder but who do not meet diagnostic criteria for disorder at that time [( WHO, 2004 ) , page 17, Box 3]. Secondary prevention seeks to lower the rate of established cases of the disorder or illness in the population (prevalence) through early detection and treatment of diagnosable diseases [( WHO, 2004 ) , page 17] Tertiary prevention includes interventions that reduce disability, enhance rehabilitation and prevent relapses and recurrences of the illness [( WHO, 2004 ) , page 17] Mental disorder prevention aims at reducing incidence, prevalence, recurrence of mental disorders, the time spent with symptoms, or the risk condition for a mental illness, preventing or delaying recurrences and also decreasing the impact of illness in the affected person, their families and the society ( Institute of Medicine, 1994 ) JID: NEUPSY [m6+; October 9, 2019; 8:5 ] ther be employed in later adulthood to improve outcomes of psychiatric disorders ( Berk et al., 2017 ; Radua et al., 2018 ) . Over the past decade, several European research sites have produced accumulating evidence in this field, generating an unexploited collaborative potential to foster breakthrough disease-modifying preventive research ( Millan et al., 2016 ) . Barriers to multidisciplinary collaboration, knowledge and data sharing, standardisation of core assessment and outcome measures and collaborative grant funding applications limit the current impact of European research in this field. A parallel line of evidence has clearly shown that effective interventions in this area should not only prevent mental ill-health, but also promote good mental health ( Sharma et al., 2017 ) . While there is an undoubtable degree of overlap between prevention of mental disorders and mental health promotion, the latter has remained on the margins in Europe, mostly because of heterogeneous assessment and outcome measures and the lack of robustly validated interventional frameworks for clinical practice ( Saxena et al., 2006 ) . This manuscript presents the first European research consortium which has been established to tackle the abovementioned limitations of knowledge, and foster research for the prevention of mental disorders and promotion of good mental health.
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Experimental procedures
This manuscript originates from a reflective workshop on the progress, challenges and future directions of the prevention of mental disorders and promotion of mental health, which was held on the October 7, 2018, at the 31st Congress of the European College of NeuroPsychopharmacology (ECNP) in Barcelona. Principal investigators from a variety of European clinical academic centres that are active in the field of prevention of mental disorders and promotion of mental health were invited to join a new ECNP Thematic Working Group on the Prevention of Mental Disorders and Mental Health Promotion (ECNP PMD-MHP). Over the subsequent year the group has received official approval and funding as full ECNP Network. During the workshop, participants also refined the Terms of Reference for the ECNP PMD-MHP Network. The current manuscript summarises the core results of this workshop, reviewing the ECNP Network structure, aims of the ECNP PMD-MHP Network, participating centres with scientific track record, industry collaborations and planned activities. The articles included in this targeted review were not selected on a systematic basis, and there is no assumption that the evidence discussed is exhaustive.
Results
ECNP network taskforce
ECNP Networks are scientific multi-disciplinary pan-European platforms that bring together researchers with different expertise for translational research collaborations in the ECNP community (see Section 3.3 ). ECNP Networks are established to facilitate the collection of essential data in a harmonised way and can focus on specific brain disorders or methodologies, flexibly supporting novel and targeted collaborations across other existing ECNP Networks. Usually, ECNP Networks and Thematic Working Groups are instigated by specific research calls or promising initiatives. The ECNP Networks are guided by the Networks Board, while each Network is led by a chair and a co-chair. Chairs and cochairs of the Networks form the ECNP Network Taskforce.
Aims of the ECNP PMD-MHP Network
Overarching aims of the ECNP Network Taskforce include fostering collaboration and gathering of experts on a specific topic, organising and promoting several Network meetings, providing administrative support, facilitating dialogue with stakeholders, supporting grant applications, and disseminating the results of funded projects.
The ECNP PMD-MHP Network was created in response to several European funding initiatives in the field of prevention of mental disorders or mental health promotion. For examples, this initiative aligns with the European Commission's ROAMER (A Roadmap for Mental Health Research in Europe). The ECNP PMD-MHP Network adopts a transdiagnostic ( Fusar-Poli et al., 2019 ) , lifespan approach to facilitate its broader integration with the other existing ECNP Networks that focus on specific brain disorders.
The ECNP PMD-MHP Network is highly multidisciplinary, including basic researchers, psychiatrists, psychologists and neuroscientists. Further multidisciplinary collaborations have been established with industry companies (see Section 3.4 ). The European sites included in the ECNP PMD-MHP Network are centres of excellence in the prevention of mental disorders and promotion of good mental health, and are part of this TWG with the following shared goals:
1. Facilitate multidisciplinary collaboration, knowledge and data sharing building on existing ECNP Networks to support innovative translational research, from basic to clinical and public health research, for the benefit of patients, focusing on the transdiagnostic disease-modifying prevention of mental disorders. 2. Standardise core assessment, outcome measures and interventional research strategies for the promotion of mental health in Europe. 3. Promote clinical research partnerships across disciplines and sectors, including public-private partnerships, in particular with the pharmaceutical firms, charities and the public. 4. Apply for European grant funding and produce research reports to disseminate the findings of the PMD-TWG Network via international journals.
Core participating centres and scientific expertise
The ECNP PMD-MHP Network is composed of core institutions with an outstanding track record in the field of prevention of mental disorders or mental health promotion. The ECNP PMD-MHP Network is co-chaired by PFP and CA. ( Spada et al., 2016 ) . This Department is studying the neurodevelopmental processes that precede the onset of major psychiatric disorders in children, the clinical and neuropsychological characteristics of help-seeking adolescents at risk of mental disorders, neuropsychological and brain imaging markers for the transition to psychosis and experimental therapeutics (e.g. FACT trial, [m6+; October 9, 2019; 8:5 ] JID: NEUPSY [m6+; October 9, 2019; 8:5 ] psychiatry departments, covering a combined catchment area of about 2.0 million people, the department is engaged in high-risk and prevention research across the region of greater Berlin region (e.g., FACT, Furthermore, the ECNP PMD-MHD Network includes members and centres and therefore expertise and infrastructures-that are already participating in other established ECNP Networks as follows:
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• Schizophrenia Network (SG, PFP, CA); 
Collaboration with the pharmaceutical industry
A key remit of the ECNP PMD-MHP Network is to foster collaborative translational research with the industry in the field of prevention of mental disorders. Researchers from Lundbeck LTD (AW), Boehringer-Ingelheim (MS) and Servier (MJM) are part of the ECNP PMD-MHP Network. The geographical composition of the core ECNP PMD-MHP Network is detailed in Fig. 1 (with the exclusion of the Boehringer-Ingelheim member from the US).
Discussion
The ECNP PMD-MHP Network is the first European infrastructure which is specifically aiming at improving the prevention of mental disorders and mental health promotion. Such an ambitious goal will be achieved through an integrated approach. First, the ECNP PMD-MHP Network will facilitate the much-needed cross-fertilisation of transdisciplinary expertise across leading European institutions that is necessary to overcome current obstacles in this area. Ideally, cross-fertilisation would ultimately be expanded to efforts to improve mental health in the elderly and to prevent neurodegenerative disorders of ageing, such as dementia, which are characterized by disabling yet often neglected psychiatric symptoms like psychosis. The ECNP PMD-MHP Network's outstanding portfolio of European and international collaborations on the prediction of outcomes in young people with emerging mental disorders, promotion of good mental health or experimental preventive interventions demonstrates its capacity to cut across different sectors and disciplines of medical, neuroscientific and psychological knowledge. Such an approach aligns with other European initiatives such as the European Alliance Against Depression ( http://eaad.net ) which was established in 2008 by a number of mental health experts from different European research to improve care and optimise treatment for patients with depressive disorders and to prevent suicidal behaviour. Second, the ECNP PMD-MHP Network will enable data sharing opportunities and harmonisation of measurements, which are essential to advance knowledge at times of big-data research. This will be facilitated through specific scientific initiatives encompassing evidence synthesis approaches, use of data-sharing cloud system, development of specific grant applications, organisation of collaborative satellite symposia and events. Third, the combination of big data and multidisciplinary collaboration will, in turn, translate into large-scale grant applications to European funding bodies. The resulting research activities are likely to improve the quality, competitiveness and efficiency of European research in the field of prevention of mental disorders and promotion of mental health. Fourth, the ECNP PMD-MHP Network will play a pivotal role in disseminating the produced outputs through open-access scientific articles, workshops, seminars and symposia organised at European conferences. Particular attention will be placed on supporting young clinicians and researchers with interest in the prevention of mental disorders and mental health promotion. Fifth, the ECNP PMD-MHP Network will liaise with national stakeholders and national policymakers to support the local implementation of evidence-based, preventive policies and efforts to promote good mental health.
Overall, these efforts are expected to blend into a new research culture that is sensitive to the prevention of mental disorders and mental health promotion, for the ultimate benefits of European citizens that may experience some frailty in their mental health.
Role of the funding source
This project was supported by the ECNP Network taskforce. The ECNP Network taskforce has no influence on the design of the study and drafting of the current manuscripts.
Declaration of Competing Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. General sources of potential conflict of interest, considered unrelated to this work include the following: CC has been a consultant and/or advisor to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. CA has been a consultant to or has received honoraria or grants from Acadia, Ambrosseti, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. PFP has been a consultant to or has received honoraria or grants from Lundbeck, Menarini, Boehringer Ingelheim. SG has been a consultant and/or advisor to or has received honoraria or grants from: Millennium Pharmaceuticals, Innova Pharma -Recordati Group, Janssen Pharmaceutica NV, Sunovion Pharmarmaceuticals, Janssen-Cilag Polska Sp. z o.o., Gedeon Richter-Recordati, Pierre Fabre, Otsuka, Angelini. 
CRediT authorship contribution statement
